This Phase 1 double blind, placebo-controlled study will evaluate the safety,tolerability, and pharmacokinetics (PK) of multiple ascending doses (MAD) of SLV213 inhealthy male and female participants, 18-65 years of age. This study will help to selectthe most likely suitable dose (e.g., at Maximum Tolerated Dose [MTD]) for the treatmentof patients with COVID-19 in a pivotal study. This phase 1 double blind,placebo-controlled study will consist of three sequential cohorts of 12 participants each(8 SLV213 and 4 placebo), at doses of 400 mg every 12 hours (Q12h), 600 mg Q12h, and 800mg Q12h administered orally (PO) for 7 days. After each cohort, a Safety Review Committee(SRC) will evaluate the safety of the regimen before proceeding to dose the next cohort.Randomization will occur into the respective cohorts as above. Upon meeting theInclusion/Exclusion criteria, subjects will begin treatment with SLV213 or placebo pertheir assigned cohort. The primary objective is to evaluate the safety and tolerabilityof multiple ascending doses of SLV213 for 7 days in healthy participants.
This Phase 1 double blind, placebo-controlled study will evaluate the safety,
tolerability, and pharmacokinetics (PK) of multiple ascending doses (MAD) of SLV213 in
healthy male and female participants, 18-65 years of age. This study will help to select
the most likely suitable dose (e.g., at Maximum Tolerated Dose [MTD]) for the treatment
of patients with COVID-19 in a pivotal study. This phase 1 double blind,
placebo-controlled study will consist of three sequential cohorts of 12 participants each
(8 SLV213 and 4 placebo), at doses of 400 mg every 12 hours (Q12h), 600 mg Q12h, and 800
mg Q12h administered orally (PO) for 7 days. After each cohort, a Safety Review Committee
(SRC) will evaluate the safety of the regimen before proceeding to dose the next cohort.
Randomization will occur into the respective cohorts as above. Upon meeting the
Inclusion/Exclusion criteria, subjects will begin treatment with SLV213 or placebo per
their assigned cohort. Participants will take their study drug in the fasted state prior
to morning and evening meals and will remain as in-patient in the clinical trial unit
(CTU) during all treatments and for approximately 48 hours (h) after the last dose for
monitoring. After discharge from the CTU, participants will be monitored by CTU staff by
telephone to assess for new adverse events and use of concomitant medication since the
last visit or contact, approximately weekly for three weeks. Participants will be asked
to return to the CTU for further assessment of moderate or severe adverse events (AEs)
use of concomitant medications (ConMeds) since the last visit or contact, approximately
weekly for three weeks. The primary objective is to evaluate the safety and tolerability
of multiple ascending doses of SLV213 for 7 days in healthy participants. The secondary
objective is to characterize the multiple dose PK of SLV213 in healthy participants.
Other: Placebo for SLV213
Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
Drug: SLV213
SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone
cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2.
SLV213 is a white powder substance without excipients or stabilizer that will be packed
into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties
against host cathepsins (e.g., Cathepsin L).
Inclusion Criteria:
1. Provision of signed and dated informed consent form.
2. Able to understand and willing to be available for all study visits and comply with
all study procedures including Lifestyle Considerations throughout the study.
3. Male and Female individuals, age 18-65 inclusive at time of enrollment.
4. Good general health by medical history (MH), physical examination (PE), and vital
signs (VS), clinical laboratory tests and Electrocardiogram (ECG) within normal
reference range.
Note 1: Lab exceptions include: lab test values that are within Grade 1 range per
the Toxicity Table (Appendix A) are acceptable if not considered to be clinically
significant by the investigator (PI, sub-investigator, or authorized clinician),
with the exception of liver function tests (LFT) (transaminases Alanine
Aminotransferase (ALT), Aspartate Aminotransferase (AST), alkaline phosphatase (AP),
total and direct bilirubin, serum creatinine, estimated glomerular filtration rate
(eGFR) per the CKD-EPI formula, and urine protein, which must be within the
laboratory normal reference range.
Note 2: Screening laboratory values that fall outside the laboratory normal
reference ranges and the ranges are not listed within the Toxicity Table (Appendix
A) (e.g., decrease activated partial thromboplastin time (aPTT)) that are deemed Not
Clinically Significant by the PI will be acceptable.
5. Ability to take oral medication and be willing to adhere to the dosing regimen.
6. Women of childbearing potential1 must have practiced or use true abstinence2 or use
at least one acceptable primary form of contraception3 for specified periods4
before, during and after dosing.
Note 1: Not of childbearing potential - post-menopausal females (defined as having a
history of amenorrhea for at least one year) or a documented status as being
surgically sterile (hysterectomy, bilateral oophorectomy, salpingectomy, tubal
ligation, or Essure placement with a history of documented radiological confirmation
test at least 90 days after the procedure).
Note 2: True abstinence is 100% of the time without sexual intercourse (the male's
penis enters the female's vagina). Periodic abstinence [e.g., calendar, ovulation,
symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of
contraception).
Note 3: Acceptable forms of primary contraception include a monogamous relationship
with a vasectomized partner who has been vasectomized for 180 days or more before
the participant receiving the study product, tubal ligation, non-hormonal,
intrauterine device, (and if in a monogamous relationship with a male partner who
uses a barrier method without spermicide) Note 4: Specified periods include at least
30 days prior to screening, during the period between screening and completion of
dosing, and until at least 30 days following receipt of the last dose of study
product.
7. Women of childbearing potential must have a negative serum Beta-human chorionic
gonadotropin (HCG) pregnancy test at screening and a negative urine HCG pregnancy
test at check-in (Day-1) within 24 hours before receiving the initial study product.
8. Male participants receiving the study product must use acceptable contraception and
refrain from donating sperm from the day of first dose until 30 days after the last
dose or be vasectomized.1 Note 1: Acceptable contraception includes abstinence from
intercourse with a female of childbearing potential or use of a male condom without
spermicide when engaging in any activity that allows for the passage of ejaculate to
a female during the intervention period and for at least 30 days after ending study
dosing, or surgical sterilization for 180 days or more.
9. Willing to avoid excessive physical exercise starting within 48 h prior to dosing
and until discharge from the CTU on Day 9.
10. No history of acute febrile or infectious illness for at least 7 days prior to the
administration of study drug.
Exclusion Criteria:
1. Pregnant or lactating.
2. History of any chronic disease that may increase risk to subject or interfere with
endpoint assessment1:
Note 1: With the exception of stable chronic medical conditions that do not require
prescribed oral or injectable medications (e.g., Type 2 diabetes managed by diet
only).
3. History of bradycardia, orthostatic hypotension or orthostatic tachycardia, Long
COVID or history of dysautonomia.1 Note 1: Exception is sinus bradycardia (HR <60
bpm) in healthy participants (e.g., conditioned athletes) could be enrolled per
investigator's clinical judgement.
4. Known history of a clinically significant food or drug allergy/hypersensitivity
including known allergy/hypersensitivity to ingredients of the study drug or
placebo.
5. Current seasonal allergies with ongoing symptoms for more than a week prior to
dosing requiring glucocorticoids and/or frequent use of antihistamines for
treatment.
6. History of any clinically significant disease or disorder, medical/surgical
procedure, or trauma within 4 weeks prior to initiation of administration of study
product(s).
7. History of any psychiatric condition that has required hospitalization in the last
12 months or subject is considered psychologically unstable by the investigator.
8. History of any substance use disorder or positive urine drug screening (UDS) test
for illicit substances at Screening or Check-in (Day -1)1.
Note 1: Any approved medical use of amphetamines, barbiturates, benzodiazepines,
cannabis, tricyclic antidepressants and opiates will not be acceptable.
9. History of alcoholism or of binge1 or heavy alcohol drinking2 at any time in the 6
months before study product administration or positive urine alcohol test at
Screening or Check-in (Day -1).
Note 1: Binge drinking is defined as 5 or more drinks during a single occasion if
male, or 4 or more if female.
Note 2: Heavy drinking of alcohol is defined as consumption of more than 14 drinks
of alcohol per week if male, or more than 7 drinks if female.
10. History of >/=10 pack-years of nicotine product1 consumption in the 5-year period
before screening, or positive urine cotinine screen at Check-in (Day -1)2.
Note 1: Nicotine products include cigarettes, e-cigarettes, pipe, cigar, chewing
tobacco, nicotine patch.
Note 2: Positive urine cotinine at Screening is allowed if negative at Check-in (Day
-1).
11. Body mass index (BMI) /= 32 kg/m2, or weight Screening.
12. Prior exposure to SLV213 or K777 or K11777.
13. Use of any prohibited prescription or non-prescription medication within 14 days or
5 half-lives of the drug, whichever is longer, prior to study Check-in.
14. Use of any investigational drug product within 30 days or 5 half-lives (whichever is
longer) before investigational product administration in this study.
15. Planned participation in a clinical research study that requires treatment with a
study drug, blood draws or other invasive assessments during the study period
(screening until final visit).
16. Blood or plasma donation of 500 mL within 3 months or more than 100 mL within 30
days before signing informed consent or planned donation prior to completion of this
trial.
17. Positive viral serology tests for Human Immunodeficiency Virus (HIV), hepatitis B
virus, or hepatitis C virus (HCV) at screening1 with one exception2:
Note 1: Viral serology tests include HIV 1 and HIV 2 antibodies, Hepatitis B virus
surface antigen (HBsAg), and HCV antibodies.
Note 2: Do not exclude participants with HCV antibodies who have been successfully
treated for Hepatitis C, do not take any treatment medications currently, do not use
prohibited medications, have normal transaminases and are generally healthy.
18. Positive SARS-CoV-2 (COVID-19) molecular diagnostic test (Cue Care™ test) at
Check-in (Day -1).
Altasciences Inc - Kansas City
Overland Park 4276873, Kansas 4273857, United States
Not Provided